Gene screening of Wharton's jelly derived stem cells.

Fiche publication


Date publication

janvier 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GANGLOFF Sophie, Pr GRAESSLIN Olivier, Dr VELARD Frédéric, Dr KERDJOUDJ Halima


Tous les auteurs :
Mechiche Alami S, Velard F, Draux F, Siu Paredes F, Josse J, Lemaire F, Gangloff SC, Graesslin O, Laurent-Maquin D, Kerdjoudj H

Résumé

Stem cells are the most powerful candidate for the treatment of various diseases. Suitable stem cell source should be harvested with minimal invasive procedure, found in great quantity, and transplanted with no risk of immune response and tumor formation. Fetal derived stem cells have been introduced as an excellent alternative to adult and embryonic stem cells use, but unfortunately, their degree of "stemness" and molecular characterization is still unclear. Several studies have been performed deciphering whether fetal stem cells meet the needs of regenerative medicine. We believe that a transcriptomic screening of Wharton's jelly stem cells will bring insights on cell population features.

Référence

Biomed Mater Eng. 2014;24(1 Suppl):53-61